In turn, the reduction in soluble IL-6 and Gal-9 levels likely contributes to improved anti-tumor immunity by alleviating the pro-tumorigenic and immunosuppressive effects of IL-6 and by disrupting the interaction between Gal-9 and the immune checkpoint receptor TIM3 on T cells. This evidence concerns the gene LGALS9 and neoplasm.